Viewing Study NCT00509574



Ignite Creation Date: 2024-05-05 @ 6:35 PM
Last Modification Date: 2024-10-26 @ 9:35 AM
Study NCT ID: NCT00509574
Status: UNKNOWN
Last Update Posted: 2010-12-13
First Post: 2007-07-29

Brief Title: Association of Genetic Polymorphisms With Lipid Lowering Effects of Statin Therapy
Sponsor: National Taiwan University Hospital
Organization: National Taiwan University Hospital

Study Overview

Official Title: Association of Genetic Polymorphisms With Lipid Lowering Effects of Statin Therapy
Status: UNKNOWN
Status Verified Date: 2010-11
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors also known as statins played an important role in lipid-lowering therapy and reduction of cardiovascular risks However it has been observed that the response to statin therapy varies from patient to patient and gene polymorphism could have contributed to the variation
Detailed Description: Hyperlipidemic patients are retrospectively screened from 200611 to 20061231 The patient is included if he or she had been receiving atorvastatin or rosuvastatin for at least 3 months and did not receive other lipid-lowering medications 4 weeks before starting atorvastatin or rosuvastatin Genomic DNA was collected from the blood sample of each patient using genomic DNA purification kit The single nucleotide polymorphisms SNPs were determined afterward

The correlation between response of statin therapy defined as changes in lipid profiles including triglyceride total cholesterol high density lipoprotein cholesterol and low density lipoprotein cholesterol and SNPs examined

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None